Erudio Healtherudio.com
Drug
Obinutuzumab trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying obinutuzumab: BiCAR. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 21 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| BiCAR NCT04703686 · The Lymphoma Academic Research Organisation | relapsed/refractory diffuse large B-cell lymphoma after CAR-T therapy | Phase 2 | 68 | 4 | Focused | Nov 17, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| CLL17 NCT04608318 · German CLL Study Group DeepView → | previously untreated chronic lymphocytic leukemia | Phase 3 | Deep | View | |||
| STARGLO NCT04408638 · Hoffmann-La Roche DeepView → | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| CLL13 NCT02950051 · German CLL Study Group DeepView → | previously untreated CLL without del(17p) or TP53 mutation | Phase 3 | Deep | View | |||
| GALLIUM NCT01332968 · Hoffmann-La Roche DeepView → | previously untreated advanced indolent non-Hodgkin lymphoma | Phase 3 | Deep | View | |||
| ELEVATE-TN NCT02475681 · Acerta Pharma BV DeepView → | previously untreated chronic lymphocytic leukemia | Phase 3 | Deep | View | |||
| ROSEWOOD NCT03332017 · BeiGene DeepView → | relapsed or refractory follicular lymphoma | Phase 2 | Deep | View | |||
| GOYA NCT01287741 · Hoffmann-La Roche DeepView → | previously untreated CD20-positive diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| LOTIS-7 NCT04970901 · ADC Therapeutics S.A. DeepView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1 | Deep | View | |||
| CLL16 NCT05197192 · German CLL Study Group DeepView → | previously untreated high-risk chronic lymphocytic leukemia | Phase 3 | Deep | View | |||
| CLL11 NCT01010061 · Hoffmann-La Roche DeepView → | previously untreated chronic lymphocytic leukemia with comorbidities | Phase 3 | Deep | View | |||
| ReVenG NCT04895436 · AbbVie DeepView → | recurring chronic lymphocytic leukemia | Phase 2 | Deep | View | |||
| NP30179 NCT03075696 · Hoffmann-La Roche DeepView → | relapsed/refractory B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Deep | View | |||
| GO29365 NCT02257567 · Hoffmann-La Roche StandardView → | relapsed/refractory follicular or diffuse large B-cell lymphoma | Phase 1/Phase 2 | Standard | View | |||
| BGB-11417-101 NCT04277637 · BeOne Medicines StandardView → | mature B-cell malignancies | Phase 1 | Standard | View | |||
| CLL2-BZAG NCT04515238 · German CLL Study Group FocusedView → | relapsed/refractory CLL | Phase 2 | Focused | View | |||
| CAVALLI NCT02055820 · Hoffmann-La Roche FocusedView → | B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Focused | View | |||
| ROMULUS NCT01691898 · Genentech, Inc. FocusedView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Focused | View | |||
| A041702 NCT03737981 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT02846623 NCT02846623 · M.D. Anderson Cancer Center FocusedView → | chronic lymphocytic leukemia, small lymphocytic lymphoma, Richter syndrome | Phase 2 | Focused | View | |||
| GLOW NCT03462719 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 3 | Focused | View | |||
| GLOASIS NCT06558604 · The Lymphoma Academic Research Organisation FocusedView → | high-risk mantle-cell lymphoma | Phase 2 | Focused | View | |||